Drug research

Namodenoson

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as CF102

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NCT04697810	Can-Fite BioPharma	Phase 2	Unknown	2025-04-15Estimated
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404	Can-Fite BioPharma	Phase 3	Recruiting	2026-02Estimated

Can-Fite BioPharmaUnknownPrimary completion: 2025-04-15 · Estimated

Trial details

Can-Fite BioPharmaRecruitingPrimary completion: 2026-02 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.